

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE  
TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**MTA for avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery**

**Batch 59/61**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company that produces lusutrombopag noted that if it is recommended, it may improve access to further treatments and reduce inequalities for certain social and religious groups by providing an alternative treatment option to platelet transfusions.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not considered an equalities issue because the potential recommendations will not make it harder for these particular groups to access treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** ...Melinda Goodall.....

**Date:** 12/10/2018